Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and DeliveryGlobeNewsWire • 04/12/22
Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 03/10/22
Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual MeetingGlobeNewsWire • 03/08/22
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)GlobeNewsWire • 01/13/22
Gritstone Says Omicron Mutations Minimally Impact T-Cell Epitope Sequences In Its COVID-19 VaccinesBenzinga • 11/29/21
Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 11/28/21
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2GlobeNewsWire • 11/10/21
Will Gritstone bio Inc. (GRTS) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/28/21
Gritstone Announces Presentations during Five Upcoming Investor Conferences and EventsGlobeNewsWire • 10/25/21
Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity EnhancerGlobeNewsWire • 09/20/21
Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal CancerBenzinga • 09/17/21
Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical TrialGlobeNewsWire • 09/17/21